223 related articles for article (PubMed ID: 25367751)
1. Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.
Desbien AL; Reed SJ; Bailor HR; Dubois Cauwelaert N; Laurance JD; Orr MT; Fox CB; Carter D; Reed SG; Duthie MS
Eur J Immunol; 2015 Feb; 45(2):407-17. PubMed ID: 25367751
[TBL] [Abstract][Full Text] [Related]
2. How squalene GLAdly helps generate antigen-specific T cells via antigen-carrying neutrophils and IL-18.
Kedl JD; Kedl RM
Eur J Immunol; 2015 Feb; 45(2):376-9. PubMed ID: 25641415
[TBL] [Abstract][Full Text] [Related]
3. MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.
Orr MT; Duthie MS; Windish HP; Lucas EA; Guderian JA; Hudson TE; Shaverdian N; O'Donnell J; Desbien AL; Reed SG; Coler RN
Eur J Immunol; 2013 Sep; 43(9):2398-408. PubMed ID: 23716300
[TBL] [Abstract][Full Text] [Related]
4. The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.
Dubois Cauwelaert N; Desbien AL; Hudson TE; Pine SO; Reed SG; Coler RN; Orr MT
PLoS One; 2016; 11(1):e0146372. PubMed ID: 26731269
[TBL] [Abstract][Full Text] [Related]
5. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses.
Fox CB; Moutaftsi M; Vergara J; Desbien AL; Nana GI; Vedvick TS; Coler RN; Reed SG
Vaccine; 2013 Dec; 31(49):5848-55. PubMed ID: 24120675
[TBL] [Abstract][Full Text] [Related]
6. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A.
Lambert SL; Yang CF; Liu Z; Sweetwood R; Zhao J; Cheng L; Jin H; Woo J
PLoS One; 2012; 7(12):e51618. PubMed ID: 23284726
[TBL] [Abstract][Full Text] [Related]
7. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.
Fox CB; Baldwin SL; Vedvick TS; Angov E; Reed SG
Clin Vaccine Immunol; 2012 Oct; 19(10):1633-40. PubMed ID: 22896687
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
[TBL] [Abstract][Full Text] [Related]
9. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.
Baldwin SL; Shaverdian N; Goto Y; Duthie MS; Raman VS; Evers T; Mompoint F; Vedvick TS; Bertholet S; Coler RN; Reed SG
Vaccine; 2009 Oct; 27(43):5956-63. PubMed ID: 19679214
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis.
Bortolatto J; Borducchi E; Rodriguez D; Keller AC; Faquim-Mauro E; Bortoluci KR; Mucida D; Gomes E; Christ A; Schnyder-Candrian S; Schnyder B; Ryffel B; Russo M
Clin Exp Allergy; 2008 Oct; 38(10):1668-79. PubMed ID: 18631348
[TBL] [Abstract][Full Text] [Related]
11. Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice.
Yu S; Tang C; Shi X; Yang P; Xing L; Wang X
Vaccine; 2012 Aug; 30(36):5425-36. PubMed ID: 22709954
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.
Orr MT; Fox CB; Baldwin SL; Sivananthan SJ; Lucas E; Lin S; Phan T; Moon JJ; Vedvick TS; Reed SG; Coler RN
J Control Release; 2013 Nov; 172(1):190-200. PubMed ID: 23933525
[TBL] [Abstract][Full Text] [Related]
13. A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: development, characterization, stability and in vivo evaluation.
Deng J; Cai W; Jin F
Int J Pharm; 2014 Jul; 468(1-2):187-95. PubMed ID: 24704309
[TBL] [Abstract][Full Text] [Related]
14. Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.
Heeke DS; Lin R; Rao E; Woo JC; McCarthy MP; Marshall JD
Vaccine; 2016 May; 34(23):2562-9. PubMed ID: 27085175
[TBL] [Abstract][Full Text] [Related]
15. Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells.
Schneider LP; Schoonderwoerd AJ; Moutaftsi M; Howard RF; Reed SG; de Jong EC; Teunissen MB
Vaccine; 2012 Jun; 30(28):4216-24. PubMed ID: 22542815
[TBL] [Abstract][Full Text] [Related]
16. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
17. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
Daifalla NS; Bayih AG; Gedamu L
Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
[TBL] [Abstract][Full Text] [Related]
18. MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine.
Singh M; Kazzaz J; Ugozzoli M; Baudner B; Pizza M; Giuliani M; Hawkins LD; Otten G; O'Hagan DT
Hum Vaccin Immunother; 2012 Apr; 8(4):486-90. PubMed ID: 22832252
[TBL] [Abstract][Full Text] [Related]
19. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.
Ahonen CL; Doxsee CL; McGurran SM; Riter TR; Wade WF; Barth RJ; Vasilakos JP; Noelle RJ; Kedl RM
J Exp Med; 2004 Mar; 199(6):775-84. PubMed ID: 15007094
[TBL] [Abstract][Full Text] [Related]
20. The importance of adjuvant formulation in the development of a tuberculosis vaccine.
Baldwin SL; Bertholet S; Reese VA; Ching LK; Reed SG; Coler RN
J Immunol; 2012 Mar; 188(5):2189-97. PubMed ID: 22291184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
